AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01679262 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Guedel type color-coded OPAs
Description: The OPAs was used four different sizes as No. 8 (80 mm, green), 9 (90 mm, yellow), 10 (100 mm, red), and 11 (110 mm, orange) in regular sequence. The curvilinear distance from the incisors to the tip of the epiglottis was measured by FOB (Olympus LF-GP; Olympus Optical Co., Tokyo, Japan) with tape marking via each size of OPAs. The distance from the distal end of OPA to the tip of the epiglottis was calculated by the difference between measured distance from the incisors to the tip of the epiglottis via each OPA by FOB and typical distance from the flange to distal end of each OPA via inside tube of OPA. When the size of OPAs was longer than distance from the incisors to the tip of the epiglottis, OPAs were partly withdrawn and repositioned the distal end of OPAs is placed just above the tip of epiglottis. Then, the length from the incisors to the flange of OPAs was measured. .
Study NCT02860884 — intervention group
Intervention type: PROCEDURE
Intervention: liver biopsy
Study NCT00107575 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment (ST)
Description: Behavioral smoking cessation counseling and nicotine patch.
Study NCT03714516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological internet intervention
Description: The intervention is a non-controlled unguided internet-based self-help intervention for adults who seek support for coping with prolonged grief symptoms after romantic bereavement or separation/ divorce. The self-help program consists of 10 text-based sessions based on cognitive-behavioral psychotherapy techniques.
Study NCT00738127 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Description: Inoue et al.'s technique is most commonly used which required placing three K-wires to immobilize both midcarpal joint and radiocarpal joint. This technique is effective, however, it has some problems. In the study, we improve the surgical technique.
Study NCT03754608 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI including cf-MRI, DTI, ASL and CVR.
Description: A paradigm developed at Yale University called Cognitive Predictive Modelling which takes connectivity data and reduces it to two smaller network which predict higher and lower performance in a particular task for which these networks have been optimized. This will be supplemented by MRI vascular measures.
Study NCT02860884 — intervention group
Intervention type: OTHER
Intervention: infrared spectroscopy
Study NCT01872741 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minipterional craniotomy
Description: Minipterional craniotomy approach for ruptured and unruptured aneurysms
Study NCT01872741 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pterional craniotomy
Description: Pterional craniotomy approach for ruptured and unruptured aneurysm
Study NCT04015388 — intervention group
Intervention type: DEVICE
Intervention: iPro Continuous Glucose Monitoring
Description: iPro device is a continuous glucose monitoring (CGM) FDA approved device. This CGM device consists of a small recorder which reports glucose values every five minutes. This recorder is connected directly to a glucose sensor. The glucose-oxidase based sensor measures extracellular fluid in the subcutaneous tissue. The tiny and flexible sensors are typically inserted just beneath the skin, usually in the abdominal area, but can also be placed in the buttock, or anterior or lateral thigh.
Study NCT02893358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corresponding placebo once daily taken in the morning during 8:00-9:00. Duration: 12 months.
Study NCT03690778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Rosuvastatin seperately
Description: administration of Metformin and Rosuvastatin seperately
Study NCT02481726 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG
Study NCT03772561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363+Olaparib+Durvalumab
Description: Patients will receive AZD5363 orally twice a day 4 days-on/ 3 days-off starting 14 days prior to cycle 1 day 1 (C1D1). Olaparib continuously twice a day at 300mg and Durvalumab intravenously at 1500mg once every 4 weeks will commence at C1D1. Treatment will continue until disease progression or the development of unacceptable toxicities.
Study NCT00412698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimonabant
Description: Administration of one tablet containing 20 mg of active rimonabantonce daily in the morning.~White film-coated tablets, for oral administration containing 20 mg of active rimonabant
Study NCT01789957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993
Description: 4-Week transition of AC2993 5 mcg subcutaneously injected twice daily followed by an open-ended period through study termination (up to 52 weeks) of AC2993 10 mcg subcutaneously injected twice daily
Study NCT00412698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of one rimonabant placebo tablet once daily in the morning. Undistinguishable placebo tablets.
Study NCT01290172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Somatostatin
Description: 6 mg will be diluted in saline in a 60 cc syringe to be infused over 24 h (250 mcg/h). The treatment will be started during the hepatectomy phase, after 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) >= 10 mmHg.~5 cc will be injected in 2 minutes as a single bolus of 500 mcg. Somatostatin will be given a second time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h(infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) >= 90 ml/min \* 100 g LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued for 5 days.
Study NCT01290172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of placebo
Description: The placebo treatment will be started during the hepatectomy phase, after the 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) >= 10 mmHg.~5 cc of the 60 cc solution will be injected in 2 minutes as a single bolus of 500 mcg. The placebo will be given a 2nd time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h (infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) >= 90 ml/min \* 100 gram LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued everyday to complete 5 days of therapy.
Study NCT02812433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
Study NCT02812433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ora-Blend
Description: Ora-Blend, 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
Study NCT00865007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monotherapy (Lopinavir/ritonavir)
Description: NRTI sparing
Study NCT00865007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monotherapy (Lopinavir/ritonavir)
Description: NRTI sparing
Study NCT00865007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monotherapy (Lopinavir/ritonavir) + ABC/3TC
Description: NRTI sparing regimen
Study NCT03605524 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sensory training
Description: 12 weeks sensory training
Study NCT00003098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fat reduction with increased fiber
Description: Patients are randomized to dietary fat reduction with increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
Study NCT00003098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fat reduction without increased fiber
Description: Patients are randomized to dietary fat reduction without increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
Study NCT03579134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: partial overlay denture
Description: removable appliance similar to a removable partial denture but with overlay occluslal rests covering the full occlusal surface of the remaining posterior teeth
Study NCT03579134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fixed temporary crowns
Description: fixed crowns made from temporary material placed to the newly altered vertical dimension
Study NCT05299567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin
Description: Placebo with the same color and size than azithromycin tree days a wek for 6 months
Study NCT05299567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Placebo with the same color and size than azithromycin tree days a wek for 6 months
Study NCT03329040 — intervention group
Intervention type: OTHER
Intervention: No Intervention.
Description: No intervention.
Study NCT01481857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmental trunk exercise associated with proprioception
Description: Proprioceptive exercise
Study NCT01481857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmental trunk exercise
Description: Segmental trunk exercise
Study NCT02181296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Study NCT04512326 — intervention group
Intervention type: PROCEDURE
Intervention: Total or Subtotal colectomy
Description: Total or subtotal colectomy (emergent or elective) with primary anastomosis (ileorectal or ileosigmoid)
Study NCT01888341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Isotretinoin Capsules,20 mg
Study NCT01888341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin Capsules,20 mg
Study NCT00809237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib, Hydroxychloroquine
Description: Gefitinib 250 mg om Hydroxychloroquine at maximally tolerated dose
Study NCT00668720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation (Magstim rapid2)
Description: Neuronavigated rTMS will be applied bilaterally to the auditory cortices, which will be identified through a structural MRI scan. Stimulation will be performed with 1 Hz frequency and an intensity of 110% motor threshold for 2000 stimuli (32 minutes) on each side, on five subsequent days.
Study NCT00668720 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: The official sham stimulator for the magstim rapid2 will be used. Sham stimulation will follow the same placement protocol and will also last 2x32 minutes on five subsequent days
Study NCT00466895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Dose level -1: 2.5 mg daily for days 1-7, 2.5 mg daily for days 8-21. Dose level 1: 2.5 mg daily for days 1-7, 5 mg daily for days 8-21. Dose level 2: 2.5 mg daily for days 1-7, 7.5 mg daily for days 8-21. Dose level 3: 2.5 mg daily for days 1-7, 10 mg daily for days 8-21. Dose level 4: 2.5 mg daily for days 1-7, 15 mg daily for days 8-21
Study NCT01853241 — intervention group
Intervention type: PROCEDURE
Intervention: Single Balloon
Description: All patients in this group will undergo single balloon enteroscopy
Study NCT02049697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-JNJ-39823277
Description: Participants will receive a single oral dose of 25 mg 14C-JNJ-39823277 as a 50-mL solution.
Study NCT01853241 — intervention group
Intervention type: PROCEDURE
Intervention: Spirus
Description: All patients in this group will undergo Spirus Enteroscopy
Study NCT02857491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: intravitreal injection of 0.5 mg ranibizumab before vitrectomy
Study NCT02857491 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sham
Description: sham intravitreal injection before vitrectomy
Study NCT02857491 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: pars plana vitrectomy
Description: surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina.
Study NCT02857491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pars plana vitrectomy
Description: surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina.
Study NCT04260750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-administered Cognitive behavioral therapy (ICBT)
Description: The intervention consists of fifteen modules, each having a specific focus on a problem (e.g. comorbid worry alongside the depression) or containing a specific strategy or element (e.g. behavioral activation).~The fifteen modules are:~Introduction/Psychoeducation about depression, Behavioral activation 1, Behavioral activation 2, Cognitive restructuring, Acceptance, Psychoeducation about emotions, Anxiety and exposure, Comorbid social anxiety, Comorbid worrying and generalized anxiety, Comorbid panic disorder, Sleep problems, Perfectionism, Stress management, Relaxation, and Relapse prevention.~The first and last module are assigned to all participants. The rest is picked either by the participants themselves or by the therapist conducting the intake interview.
Study NCT04357119 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-anastomosis gastric bypass
Description: Laparoscopic single anastomosis gastric bypass is reported to be a safe alternative to LRYGB, showing comparable efficacy in weight reduction and resolution of metabolic complications with reduced surgical complications.~The advantages with this technique as claimed by those speaking in favor of it are many: fewer sites for leakage and internal hernia, easier and faster to learn and perform, easy to reverse and revise, and with results at least comparable with the result following standard Roux-en-Y gastric bypass (RYGB).~The length of the biliopancreatic limb in single anastomosis gastric bypass as reported by Rutledge is fixed 200 cm starting at the duodenojejunal junction, neglecting the length of the common limb.~Because of deficient data regarding the effect of common limb length on the outcome of LSAGB, so a clinical trial shall add new knowledge regarding sufficient weight loss, rate of complications and the need for revision.
Study NCT03988257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Imunoglukan PH4
Description: Children allocated to experimental group will receive Imunoglukan PH4 syrup (10 mg of pleuran and 10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (\< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.
Study NCT03988257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vitamin C syrup)
Description: Children allocated to control group will receive a placebo: a vitamin C syrup (10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (\< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.
Study NCT01201798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05% ophthalmic emulsion
Description: 1 drop in study eye, 4 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
Study NCT01201798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate 1.0% ophthalmic suspension
Description: 1 drop in study eye, 8 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
Study NCT03147274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Patients randomized to the intervention group will attend 3 SMART T1D group curriculum sessions over the study period, in addition to usual diabetes clinic care. Each interactive group session will last 2 hours and will be facilitated by a diabetes nurse educator.
Study NCT03949309 — intervention group
Intervention type: OTHER
Intervention: Exploring health literacy levels and patients' informal needs or individual relationship between caregivers and patients.
Description: It is a cross-sectional study coupled with a qualitative ancillary study conducted within patients hospitalized for one of the two acute cardiovascular diseases (acute coronary syndrome or acute heart failure). All patients hospitalized at Hospices Civils de Lyon for one of these two diseases and whom are going back home will be enrolled. Few patients will be interviewed during the follow-up visit at 1-month post hospitalisation. Caregivers from cardiology units will also be interviewed.
Study NCT04396340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XMT-1592
Description: XMT-1592 will be administered once every 21 or 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.
Study NCT01393119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-758
Description: 3-fluoro-N-( 4-fluorophenyl)-4-hydroxy-N-( 4-hydroxyphenyl) benzamide; a nonsteroidal selective estrogen receptor (ER) a agonist
Study NCT03690778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1310
Description: administration of JLP-1310
Study NCT00278161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg SQ 24-48 hours after last dose of cyclophosphamide.
Study NCT00278161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2/day on Days 1, 4, 8, 11, 45, and 52.
Study NCT00278161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg/day on Days 15, 16, 17, and 18.
Study NCT05168761 — intervention group
Intervention type: PROCEDURE
Intervention: partial nephrectomy
Study NCT04556617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX2853
Description: PLX2853 tablets
Study NCT04556617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib tablets
Study NCT04556617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate tablets
Study NCT04556617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone (or equivalent) tablets
Study NCT00950404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viagra 50 mg tablet
Description: Commercial tablet, 50 mg, single dose administered with water
Study NCT00950404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B ODT tablet 50 mg
Description: Oral disintegrating tablet (ODT), 50 mg, single dose administered without water
Study NCT00950404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C ODT tablet 50 mg
Description: ODT, 50 mg, single dose administered without water
Study NCT00950404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D ODT tablet 50 mg
Description: ODT, 50 mg, single dose, administered without water
Study NCT03646123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.2 mg/kg by IV infusion
Study NCT03646123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 25 mg/m\^2 by IV infusion
Study NCT03646123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: 6 mg/m\^2 by IV infusion